Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy

BACKGROUND: Secondary dystroglycanopathies are a subset of muscular dystrophy caused by abnormal glycosylation of α-dystroglycan (αDG). Loss of αDG functional glycosylation prevents it from binding to laminin and other extracellular matrix receptors, causing muscular dystrophy. Mutations in a number...

Descripción completa

Detalles Bibliográficos
Autores principales: Foltz, Steven J., Luan, Junna, Call, Jarrod A., Patel, Ankit, Peissig, Kristen B., Fortunato, Marisa J., Beedle, Aaron M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890530/
https://www.ncbi.nlm.nih.gov/pubmed/27257474
http://dx.doi.org/10.1186/s13395-016-0091-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890530/
https://www.ncbi.nlm.nih.gov/pubmed/27257474
http://dx.doi.org/10.1186/s13395-016-0091-9

Ejemplares similares